Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Ibogaine Clinical Trials topic
No spam. Unsubscribe anytime.
Committee advances bill to fund ibogaine clinical trials using opioid settlement funds
Summary
Lawmakers advanced HB314 to create a tightly controlled pathway for FDA-regulated ibogaine trials, proposing $5 million in state opioid-settlement seed money with required matching funds and oversight from a consortium of a drug developer, a university and a hospital.
Senator Harkins introduced House Bill 314 to authorize the Department of Health to select and fund a consortium to conduct FDA-regulated ibogaine clinical trials aimed at opioid use disorder, co-occurring substance-use disorders and related neurological conditions. "The core purpose is the act authorizes the State Department of Health to select and fund a consortium to conduct an Ibogaine development drug clinical trial aimed at securing FDA approval," he said.
Doctor Rourke, called to offer technical comments, described screening and safety protocols: pretreatment EKGs to identify cardiac risk, a single ibogaine administration producing an approximately 12-hour psychedelic experience, and about 48 hours of acute monitoring before return to usual care. Committee discussion covered costs and scale: proponents estimated roughly $50,000 per ibogaine treatment episode and proposed using $5,000,000 from opioid settlement funds with matching non-state dollars to seed a multistate consortium. After debate on trial design and oversight, the committee voted to advance the bill; the chair said the ayes have it.
